198 related articles for article (PubMed ID: 37020570)
41. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
42. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.
Sangroongruangsri S; Kittrongsiri K; Charatcharoenwitthaya P; Sobhonslidsuk A; Chaikledkaew U
Clinicoecon Outcomes Res; 2021; 13():703-715. PubMed ID: 34349534
[TBL] [Abstract][Full Text] [Related]
43. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
45. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
46. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X
Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205
[TBL] [Abstract][Full Text] [Related]
47. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
48. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
49. Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands.
Uyl-de Groot CA; van Rooijen EM; Punt CJA; Pescott CP
Health Econ Rev; 2018 Jul; 8(1):13. PubMed ID: 30019286
[TBL] [Abstract][Full Text] [Related]
50. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
[TBL] [Abstract][Full Text] [Related]
51. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
[TBL] [Abstract][Full Text] [Related]
52. Population based screening for chronic kidney disease: cost effectiveness study.
Manns B; Hemmelgarn B; Tonelli M; Au F; Chiasson TC; Dong J; Klarenbach S;
BMJ; 2010 Nov; 341():c5869. PubMed ID: 21059726
[TBL] [Abstract][Full Text] [Related]
53. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
54. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
57. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
58. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
59. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
60. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]